Drug Trial Radar · NCT06404905
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 24, 2024
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
BT02 monoclonal antibody injectionDrug
It is expected to include 10-30 patients assigned to dose escalation cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting ToxicityTime frame: Within day 28 after administration
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Within day 28 after administration
- Maximum tolerated doseTime frame: Within day 28 after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital
Beijing, Biejing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.